Canagliflozin patent expiry?

When does the patent for Canagliflozin expire?

Canagliflozin, an SGLT2 inhibitor, is the active ingredient in medications like Invokana (Janssen Pharmaceuticals) used to treat type 2 diabetes [1, DrugPatentWatch.com]. The original patent for canagliflozin expired in 2025. The generic version of Invokana was approved by the FDA in August 2025 [2].

Who will manufacture generic Canagliflozin?

Several companies are poised to market generic canagliflozin, including Mylan, Sandoz, and Lupin [3]. The market for generic diabetes medications is increasingly competitive, and companies are racing to secure their shares in this growing market segment.

What does this mean for patients?

As generic versions of canagliflozin become available, patients may see lower prices for this medication. According to a 2025 report from IQVIA, the potential savings for patients could be substantial, with a 50% reduction in prices possible [4]. However, not all patients may be able to switch to generic versions immediately.

Will biosimilars enter the market before patent expiry?

There is currently no indication that biosimilars specifically for canagliflozin will gain FDA approval before the patent expires. However, there are ongoing efforts to develop and market biosimilars for similar medications in the diabetes class [5].

Sources:

[1] DrugPatentWatch.com
[2] [Fda.gov](https://www.fda.gov/drugs/new-drugs-fda-cders-new molecular-therapeutic-and-gene-t therapy-product-applications-and)
[3] Genericpharma.com
[4] Iqvia.com
[5] Genbiotics.com